Cullinan reports $439M cash, $219.9M net loss; CLN-978 data and zipalertinib NDA on track

Cullinan Therapeutics, Inc.

Cash and investments of $439.0M as of Dec 31, 2025; runway into 2029.
Net loss of $50.7M in Q4 2025 ($219.9M full year), vs $47.6M in Q4 2024.
Initial clinical data for CLN-978 in SLE and RA confirmed for Q2 2026; repeat dosing data in RA in Q3 2026.
Zipalertinib rolling NDA submission completed; REZILIENT3 frontline study enrollment completed, top-line results by year-end 2026.
Cullinan eligible for $30M upon 2L U.S. approval, up to $100M upon 1L, plus 50/50 profit share.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Cullinan Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2025 results: net income Net loss attributable to Cullinan was $50.7 million for the fourth quarter of 2025, compared to $47.6 million for the sa.

Period: the fourth quarter and full year ended December 31, 2025
Net income: Net loss attributable to Cullinan was $50.7 million for the fourth quarter of 2025, compared to $47.6 million for the sa
Result: reported results

Exact text from the filing

On March 10, 2026, Cullinan Therapeutics, Inc. (the "Company") announced its financial results for the year ended December 31, 2025.

View on SEC.gov

Browse all earnings releases →

Cullinan Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-099355

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.